Martin Leblanc

President and CEO, Caprion Proteomics Inc.
President, Personalized Medicine Partnership for Cancer (PMPC)

A co-founder of Caprion, Mr. Leblanc has led the development of Caprion’s proteomics technology platform to a profitable and rapidly growing service business in the field of drug discovery, biomarker development and personalized medicine. Caprion has sustained a growing number of strategic alliances with over 50 major pharmaceutical and biotechnology companies as well as with leading government agencies and academic institutions. He also concluded successful acquisitions as well as the recent sale of Caprion to Chicago Growth Partners, a leading healthcare private equity firm.

Prior to Caprion, Mr. Leblanc began his professional career as a management consultant with McKinsey & Company. He then initiated his career as a biotech entrepreneur at Advanced Bioconcept, initially as Vice-President of Sales & Marketing and then as General Manager following the company’s acquisition by NEN Life Sciences (now part of Perkin-Elmer). Mr. Leblanc is currently a member of the Governing Council of the Canadian Institutes of Health Research (CIHR), and of the Board of Directors of Cytovance Biologics, Victhom Human Bionics, Montreal In-Vivo and the Atlantic Cancer Research Institute. Mr. Leblanc earned his bachelor’s degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.